Novartis AG
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vasant Narasimhan
- Full Time Employees
- 75,883
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Lichtstrasse 35 Basel Switzerland 4056
- IPO Date
- Nov 7, 1996
- CIK
- 0001114448
- Website
- novartis.com
- Similar Companies
- Business
- Novartis AG (NVS), a Swiss multinational pharmaceutical company headquartered in Basel and founded in 1996 through the merger of Ciba-Geigy and Sandoz, develops, manufactures and markets innovative medicines focused on oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases; key products include Kisqali (ribociclib) for breast cancer, Cosentyx (secukinumab) for psoriasis and arthritis, Entresto (sacubitril/valsartan) for heart failure, Kesimpta (ofatumumab) for multiple sclerosis, Pluvicto for prostate cancer, Scemblix (asciminib) for leukemia, Leqvio for cholesterol reduction, Zolgensma for spinal muscular atrophy, and radioligand therapies alongside gene and cell therapies like Kymriah (tisagenlecleucel). The company operates globally with major research hubs in Cambridge, Massachusetts, and expanded facilities in the US including a new San Diego research center planned for 2028-2029 and manufacturing investments totaling over $23 billion across 10 sites to achieve 100% end-to-end US production of key medicines by end-2025; it spun off its generics division Sandoz in October 2023 and Alcon eye care in 2019 to sharpen focus on high-value innovative medicines. Recent strategic moves include the October 2025 $12 billion acquisition of Avidity Biosciences to bolster RNA therapeutics for neuromuscular diseases, completion of Tourmaline Bio acquisition for pipeline enhancement, February 2025 purchase of Anthos Therapeutics for $925 million in cardiovascular assets, April 2025 agreement to acquire Regulus Therapeutics for up to $1.7 billion in microRNA therapies, plus licensing deals with Argo Biopharma, Arvinas, Arrowhead Pharmaceuticals and Dren Bio exceeding $17 billion in potential value to offset patent losses and drive 5-6% compound annual sales growth through 2030.
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Experimental Novartis radiopharma drug shows promise in early study
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
3 International ETFs for Investors Looking Beyond U.S. Stocks
Cancer Stocks That Are Advancing the Future of Oncology Care
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
Implied Volatility Surging for Novartis Stock Options
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Novartis to cut 220 jobs as it closes German site
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
Concurrent Investment Advisors LLC Grows Position in Novartis AG $NVS
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Novartis: Revenue Lags In Q1, Outlook Unchanged
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down
Novartis (NVS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Novartis shares fall after weak Q1 hit by Entresto competition